The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
Settlement agreement and payment related to the sale of the Offset Solutions division March 31, 2026 – 5.40 PM CET Regulated information Settlement agreement and payment related to the sale of the Offset Solutions division Mortsel, Belgium – March 31, 2026 – 5.40 PM CET The Agfa-Gevaert Group today announced that it has entered into a settlement agreement in relation to the purchase price adjustment and certain other outstanding claims arising from the sale of Agfa’s Offset Solutions division entered into in 2022. In January 2026, the independent...
Dading en betaling in verband met de verkoop van de divisie Offset Solutions 31 maart 2026 – 17u40 CET Gereglementeerde informatie Dading en betaling in verband met de verkoop van de divisie Offset Solutions Mortsel, België – 31 maart 2026 – 17u40 CET De Agfa-Gevaert Groep heeft vandaag bekendgemaakt dat zij een dading heeft gesloten met betrekking tot de aanpassing van de aankoopprijs en bepaalde andere uitstaande vorderingen in verband met de verkoop van Agfa’s divisie Offset Solutions in 2022. In januari 2026 bracht de onafhankelijke expert het eindrapport uit, waarin een prijsaanp...
UCB announced that the European Commission approved Kygevvi (doxecitine and doxribtimine) under exceptional circumstances as the first and only treatment for paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. The approval comes after the positive CHMP opinion announced in February 2026. Beyond the EU, the product received FDA approval in the US in 4Q25. € 284 TP and BUY maintained.
CTP: Asian financings. KPN: Increases internet prices and discontinues 100Mbit/s fiber optic subscription. Magnum Ice Cream Company: Closing the acquisition of Kwality Wall's in India. SBM Offshore: Mopane 2028? Staffing Sector: Belgium staffing February Temp volume decline moderating on easier comps; stable underlying but blue collar softer. Unilever plc: Morris dancing reaches its climax. Universal Music Group: €500m buyback welcome, management stresses dislocated valuation. WDP:...
We updated our model (€ 1.0 Target Price maintained) after Agfa delivered a clearly improved 4Q25, with adj. EBITDA up 28% y/y to € 39m and FCF of € 44m, bringing FY25 FCF to a positive € 35m. This late-year rebound partly masks a challenging FY25, which remained dominated by structural pressure in Radiology, the dilutive impact of the ongoing cloud transition in HealthCare IT, and rising uncertainty linked to silver price volatility. Agfa remains confident in the strategic direction of its “Gro...
UCB presented updated data for Bimzelx in hidradenitis suppurativa (HS) and psoriasis (PsO) at the AAD conference, held 27–31 March. In HS, data showing better outcomes in patients with lower disease duration and severity makes the case for earlier treatment with Bimzelx, further supporting the drug's continued commercial uptake. In PsO, we're encouraged to see high rates of complete skin clearance up to 4 years in patients that stopped and re-started treatment, which should help UCB capture re-...
FY2025 disappointed, 2026 looks soft, and we see a risk that negative news flow will persist. While the long-term growth case remains intact, timing is key. We therefore downgrade to Neutral and await clearer signs of a demand inflection.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.